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Background: Two new therapies for fecal incon-
tinence (FI) are now available: non–animal stabilized
hyaluronic acid and dextranomer copolymer (NA-
SHA/Dx) and sacral nerve stimulation (SNS).
Purpose: This study aimed to determine the cost-
effectiveness of NASHA/Dx compared with SNS and
conservative therapy (CT) for the treatment of FI after
CT failure.
Methods: Decision tree models with Markov sub-
branches were developed to compare all direct costs
and outcomes during a 3-year period from the view-
point of the US third-party payer. Costs (in 2013
US dollars) of devices, medical and surgical care,
and hospitalization were included. Outcomes included
quality-adjusted life-years (QALYs) and incontinence-
free days (IFDs). Both costs and outcomes were
discounted at an annual rate of 3%. The incremental
cost-effectiveness ratio was calculated for each out-
come. One-way and probabilistic sensitivity analyses
were performed to examine robustness of results
and model stability. A budget impact analysis was
also undertaken to estimate the potential cost and
savings of NASHA/Dx for a payer with 1,000,000
covered lives.
Results: For the 3-year cost-effectiveness models, the
expected cost was $9053 for CT, $14,962 for NASHA/
Dx, and $33,201 for SNS. The numbers of QALYs were
1.769, 1.929, and 2.004, respectively. The numbers of
IFDs were 128.8, 267.6, and 514.8, respectively. The
incremental cost-effectiveness ratios per additional IFD
gained were $42.60 for NASHA/Dx vs CT, $73.76 for
SNS vs NASHA/Dx, and $62.55 for SNS vs CT. The
incremental costs per QALY gained were $37,036 for
NASHA/Dx vs CT, $244,509 for SNS vs NASHA/Dx,890and $103,066 for SNS vs CT. The budget impact
analysis evaluated the ﬁnancial effect on the health care
system of the use of NASHA/Dx and SNS. For the
scenarios evaluated, when all of the patients receive
NASHA/Dx, the net annual effect to the health care
payer budget ranged from $571,455 to $2,857,275.
When all of the patients receive SNS, the net annual
effect to the health care payer budget ranged from
$1,959,323 to $9,796,613.
Conclusion: Both NASHA/Dx and SNS have pro-
duced signiﬁcant improvements in FI symptoms for
affected patients. NASHA/Dx is a cost-effective and
more efﬁcient use of resources for the treatment of FI
when compared with SNS. The budget impact analysis
suggests that although reimbursement for NASHA/Dx
treatment initially adds costs to the health care system,
it is signiﬁcantly less expensive than SNS for patients
who are candidates for either treatment. (Clin Ther.
2014;36:890–905) & 2014 The Authors. Published by
Elsevier HS Journals, Inc.
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INTRODUCTION
Fecal incontinence (FI) is a socially devastating con-
dition of varied origin. Conservative therapy (CT)Volume 36 Number 6
M.A. Bernstein et al.includes dietary changes, bulking agents, antidiarrheal
medications, enemas, and biofeedback. Contingent on
the severity of the incontinence, these noninvasive
measures are often initial options. Conservative ther-
apy can successfully improve FI in 430% to 50% of
affected individuals.1–4 When CT is unsuccessful,
other therapies may be considered. Anal sphincter
repair, artiﬁcial bowel sphincter, muscle transfers,
radiofrequency, and stomas are other treatment op-
tions for FI available in the United States. Historically,
repair of anterior defects was favored; however, more
recent research has revealed poor long-term results.5,6
Although an attractive alternative with often impres-
sive long-term functional results, artiﬁcial bowel
sphincter was found to have a 40% major infection
rate, limiting its appeal.7,8 Muscle transfers are com-
plex and associated with a high morbidity; thus, they
have not been widely popularized. Radiofrequency
collagen reformation is a promising modality but
requires an anesthetic and an operating room or
endoscopy suite for its application. A diverting stoma
allows affected patients to function away from the
toilet but interferes with their overall quality of life.
More recently, 2 therapies for FI have been ap-
proved by the US Food and Drug Administration
(FDA), including non–animal stabilized hyaluronic
acid and dextranomer copolymer (NASHA/Dx*),
approved in May 2011, and sacral nerve stimulation
(SNS†), approved in March 2011. NASHA/Dx is a
bulking agent that consists of dextranomer
microspheres in stabilized hyaluronic acid, which are
injected into the submucosa. In the prospective
randomized study conducted for FDA approval of
NASHA/Dx, 52% of patients had a 450% reduction
of FI versus 31% of sham-treated patients after 6
months (P ¼ 0.009).4 These results were sustained in
the NASHA/Dx treatment group at 36 months.9 A
separate 24-month follow-up study evaluated the
effectiveness of NASHA/Dx for FI under open-label
conditions; 62.7% of the patients were treatment
responders and experienced at least a 50% reduction
in the total number of FI episodes.10
SNS has also produced major clinical beneﬁts for
patients with FI.11–15 This therapy involves the*Trademark: Solestas (Salix Pharmaceuticals, Raleigh, North
Carolina)
†Trademark: InterStims (Medtronic Inc, Minnetonka,
Minnesota).
June 2014administration of long-term low-level electrical im-
pulses to stimulate the sacral sensory and motor ﬁbers.
The SNS procedure is a staged process in which the
patient ﬁrst undergoes insertion of an electrode at-
tached to an external pulse generator to assess beneﬁt.
If there is a 450% reduction in FI, a permanent
electrode is inserted and connected to an implanted
pulse generator. The mechanism of action of SNS
includes local sensory improvement, probably secon-
dary to cortical stimulation.16 In the 12-month
study conducted for FDA approval of SNS, 90% of
patients passed test stimulation and proceeded to
long-term implantation; for those patients who re-
ceived permanent implantation, 83% had therapeutic
success, with 41% achieving complete continence.15
In a long-term study of SNS, Hull et al17 found
sustained success, with 89% having a 450%
reduction in FI at Z5 years and 36% having
complete resolution of FI.
Considering the various treatment interventions for
individuals in whom CT fails and the associated cost
burden, a number of studies of the cost-effectiveness
of interventions with SNS for FI have been per-
formed.18–24 In most cases, SNS was cost-effective,
dominating in one Markov analysis from the Nether-
lands.24 A simulation model evaluating the cost-
effectiveness of SNS treatment for FI in patients with
an intact anal sphincter estimated an incremental cost-
effectiveness ratio (ICER) of €38,662 per quality-
adjusted life-year (QALY) gained in the Italian health
care system.18 A similar simulation model developed
to assess the cost-effectiveness of SNS treatment for a
comparable patient population in the Spanish health
care system yielded an ICER of €16,181 per QALY
gained with minimal budget impact.21 This latter
model was validated using a prospective comparison
of 2 patient cohorts.23 The exception was a study
from France comparing 2 patient cohorts; that study
found signiﬁcantly higher ICERs.22 Patients with FI
who underwent implantation with sacral nerve
modulation experienced improved disease-related
quality of life when compared with patients without
implants, but at an increased cost. For the FI patients,
the 12- and 24-month ICERs were €90,082 and
€185,160, respectively.
Although studies have investigated the cost-
effectiveness of SNS, there is no published literature
evaluating the cost-effectiveness of NASHA/Dx. In addi-
tion, no comparison has been made between these 2891
Clinical Therapeuticstreatment options to guide health care professionals in
choosing one treatment option over the other for affected
patients. The objective of the present study was to
determine the cost-effectiveness of NASHA/Dx compared
with SNS after failure of CT in the United States.
METHODS
A modiﬁed decision tree was used to analyze costs and
QALYs for adult patients who have had FI symptoms
for at least 12 months and did not respond adequately
to CT.4,15 Figure 1 depicts the primary model
structure. The analytic viewpoint was that of the US
health care payer during a 3-year period.
Model Structure
A hybrid model was developed to compare costs and
outcomes between NASHA/Dx with other options after
CT failure. The modeling procedure was guided by the
published literature and a panel of clinical experts in this
ﬁeld. To determine suitable treatment options, a literature
review was performed, followed by a survey of practicing
clinicians (see the Supplemental Survey 1 in the online
version at http://dx.doi.org/10.1016/j.clinthera.2014.04.
010). That survey was undertaken at the 23rd Annual
International Colorectal Disease Symposium (Fort
Lauderdale, Florida, February 2012). The question-
naires captured physician experiences and preferences
regarding the testing, diagnosis, and treatment of FI. The
survey was ﬁelded to 50 clinicians, and 35 surveys wereSuccess
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Figure 1. Three Year Cost-effectiveness Model. FI = feca
hyaluronic acid and dextranomer copolymer; S
892returned and analyzed (ie, 70% response rate). The
survey responses indicated that SNS and NASHA/Dx
were suitable treatment options. This information was
used to construct the model, which reﬂected US practice.
The options for this analysis included continuing
to receive CT (ie, the “do nothing” option), using
NASHA/Dx, and undergoing SNS. Typically, CT in-
volves dietary changes, bulking agents, antidiarrheal
medications, glycerin suppositories, enemas, biofeed-
back, and other noninvasive measures.1–4 NASHA/Dx
requires Z1 injections of dextranomer microspheres in
stabilized hyaluronic acid into the submucosa, whereas
SNS involves the surgical implantation of a stimulation
device under the skin to modulate neuronal impulses.
All treatment arms have an initial 6-month treat-
ment phase (Figure 1) followed by Markov submodels
that are 30 months in length, for a total period of 3
years (Figure 2). The cycle length is 1 month, which is
based on having a reasonable period for a series of
biofeedback treatments for FI. A half-cycle correction
was not used for the Markov submodels because of
the relatively short cycle length. Baseline medical
management costs for patients with FI were estimated
from the published literature.25 On the basis of
physician guidance, biofeedback was included as a
potential downstream treatment option for patients
who did not achieve primary treatment success with
NASHA/Dx or SNS. The model structures for CT and
NASHA/Dx were identical; the SNS arm containsMarkov Sub-
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Figure 2. Markov Submodel. FI = fecal incon-
tinence. *The treatment is biofeedback
therapy.
M.A. Bernstein et al.additional nodes to reﬂect the 2-stage process for the
SNS procedure (ie, the initial stimulation phase and
the implantation phase). The cost-effectiveness model
that evaluated incontinence-free days (IFDs) as the
outcome used the expected cost from the hybrid
model and the 3-year discounted IFD values, which
were calculated separately. The hybrid cost-
effectiveness model was developed using TreeAge
Pro 2014 (TreeAge Software Inc, Williamstown,
Pennsylvania). The discounting and ICER calculations
for the IFD outcome were evaluated in Microsoft
Excel 2010 (Microsoft Corp, Redmond, Washington).Clinical Inputs
PubMed was reviewed for relevant studies pertain-
ing to these interventions for the years 2004 to 2013.
For the SNS group, PubMed was searched for the title
keywords sacral nerve stimulation and fecal incon-
tinence. For the NASHA/Dx group, PubMed was
searched for the title keywords NASHA/Dx or hya-
luronic acid and fecal incontinence or faecal incon-
tinence. At the abstract level, it was required that
studies reported the Responder50 end point for pri-
mary patient data. At the title level, the search resulted
in 59 articles for SNS and 6 for NASHA/Dx. One study
was not indexed on PubMed and was provided by an
adviser.9 After the studies were reviewed at the abstract
level, 9 remained for SNS and 5 for NASHA/Dx. After
review at the manuscript level, 5 studies were used to
provide data for the SNS group, and 5 studies were
used to provide data for the NASHA/Dx group. The
efﬁcacy estimates were computed for 12, 24, and 36June 2014months for SNS.13,15,26–28 The efﬁcacy estimates were
computed for 6, 12, 24, and 36 months for NASHA/
Dx.4,9,10,29,30 The sample size weighted means were
computed using the study sample sizes and the propor-
tions of individuals who met the Responder50 end point
at the respective time points. The efﬁcacy estimate for
the stimulation phase of SNS was derived from a
multicenter prospective study.13,15 Table I summarizes
the weighted mean success rates used as model inputs.
The cost-effectiveness calculations for the IFD outcome
use the number of IFDs for the CT group as the baseline
value for the ICERs, which include CT.
Costs
Because the perspective is that of the health care payer,
indirect costs were not included in the model. All direct
costs were expressed in 2013 US dollars. The cost
estimate for CT was drawn from a published study that
reported the mean per person direct medical costs
associated with FI.25 These costs include physician
visits, laboratory tests, operations, hospitalizations,
medications, and home health care.25 Since this cost
was published using 2010 US dollars, it was adjusted to
2013 US dollars using the medical component of the
Consumer Price Index values for mean yearly change.
31–33 For NASHA/Dx, the cost was provided by the
manufacturer (Salix Pharmaceuticals, Raleigh, North
Carolina). Because a speciﬁc Current Procedural Termi-
nology orHealthcare Common Procedure Coding System
code for anoscopy with injection of NASHA/Dx does
not currently exist, an estimated charge was developed
using crosswalks to similar gastrointestinal endoscopic
procedures.
Unit costs assigned to resources consumed were
derived from Centers for Medicare and Medicaid
Services sources, as available (Table II).34–36 Physician
reimbursement (under a dedicated Current Procedural
Terminology code) for the NASHA/Dx procedure was
not currently available from Centers for Medicare and
Medicaid Services; therefore, an estimated cost was
assumed using similar procedures and guided by
expert opinion. Biofeedback and the associated cost
were included for treatment nonresponders for the last
30 months of the model. The cost of medical manage-
ment was included in the last 30 months for all
patients. This cost of medical management is the same
value that is used for CT as previously noted.25 For
the SNS and NASHA/Dx treatment arms, the medical
management costs were decreased by 50% for893
Table I. Probability inputs for the cost-effectiveness model.
Variable Value (SE) Reference(s)
Conservative therapy
Treatment success at 6 months 0.31 (0.0553) 4
IFDs at 6 months 0.85* (NA†) 4
NASHA/Dx
Treatment success
6 Months 0.543‡ (0.0444) 4, 29
12 Months 0.613‡ (0.0558) 9, 29, 30
24 Months 0.627 (0.0531) 10
36 Months 0.588 (0.0447) 9
IFDs
1 Year 1.75* (NA†) 4
2 Years 1.775* (NA†) 10
Subsequent treatment rate (weighted mean) at 1 month 0.634‡ (NA†) 4, 10
Sacral nerve stimulation
Test stimulation success§ 0.90 (0.0260) 15
Treatment success
12 Months 0.791 (0.0599) 15, 27, 28
24 Months 0.809 (0.0796) 13, 26, 27
36 Months 0.848 (0.1055) 13, 27
IFDs
1 Year 3.40* (NA†) 15
2 Years 3.20* (NA†) 13
3 Years 3.60* (NA†) 13
IFDs ¼ incontinence-free days; NA ¼ not applicable; NASHA/Dx ¼ non–animal stabilized hyaluronic acid and dextranomer
copolymer.
*Presented as days per week.
†Simulations and sensitivity analyses are not performed for IFD outcome.
‡Where multiple estimates were available from more than one study, a weighted mean was computed (weighted by sample
size). In cases where multiple estimates were not available, the estimate from only one study was used. For 1 year and 3
years, the weighted mean estimates were the estimates used in the models.
§The test stimulation phase is relatively short (usually 10–14 days).
Clinical Therapeuticspatients who achieved treatment success. All costs and
outcomes were discounted at 3% per annum, as per
current recommendations.37
Outcomes
Outcome measures of effectiveness were QALYs and
IFDs. Quality-of-life values (utility values) were assigned
based on whether the patient was experiencing FI
symptoms during the model period (Table I). QALYs
were not derived directly from studies of NASHA/Dx or
SNS because generic health preference outcomes were not
available. Values were derived from published studies that894evaluated European Quality of Life–5 Dimensions scores
and estimated utility values for FI patients dependent on
their symptomatic status.18,38 A utility value of 0.55 was
assigned for periods associated with FI symptoms,
whereas a utility value of 0.74 was assigned for periods
associated with adequate relief of FI symptoms, which
was deﬁned as success with respect to the Responder50
end point.
Statistical Analysis
The economic outcome of the analysis was the ICER
for each of the outcomes of interest, which wereVolume 36 Number 6
Table II. Cost inputs for the cost-effectiveness model.
Variable Time Cost, $a Cost Range, $a Reference
Conservative therapy cost Annual 2584b 2067–3101 25
NASHA/Dx costs
Physicianc NA 281.03 224.82–337.23 34
Device NA 4900 2940–6860 g
SNS (stimulation phase) costd NA 6792 5433–8150 35
SNS (implantation) coste NA 29,027 23,221–34,832 35
Biofeedback session cost Monthf 265.45 212.36–318.55 36
aAll costs are in 2013 US dollars.
bCost was published in 2010 US dollars, adjusted to 2013 US dollars using the medical component of the Consumer
Price Index.
cCurrent Procedural Terminology code 46221.
dTest stimulation for SNS (Current Procedural Terminology code 64581).
e2013 Medicare national mean for complete (permanent implantation) SNS procedure.
fBiofeedback sessions (assumption is 3 treatments per week).
gSalix Pharmaceuticals, Raleigh, North Carolina.
M.A. Bernstein et al.expressed as the incremental cost per QALY gained and
per IFD gained during the 3-year period. To evaluate
the robustness of model outcomes, 1-way sensitivity
analyses were performed for cost inputs, probabilities,
and utilities. For 1-way sensitivity analyses, plausible
ranges were used to investigate the effect of deviations
on a per variable basis. One-way sensitivity analyses
were presented in ICER tornado diagrams (Figures 4–
6). One-way sensitivity analyses were computed for the
NASHA/Dx cost input, the decrease in medical manage-
ment costs for treatment responders in the NASHA/Dx
and SNS arms, and the NASHA/Dx subsequent treat-
ment rate (Tables V–VII).
A probabilistic sensitivity analysis was performed to
evaluate the overall variability of model outcomes using
10,000 iterations. The SEs for the probability values
were estimated using the formula for binomial propor-
tions and were used as the measure of variability in the
probabilistic sensitivity analysis. Cost inputs were
modeled as lognormal distributions, and probability
and utility variables were modeled as β-distributions
(see the Supplemental Table I in the online version at
http://dx.doi.org/10.1016/j.clinthera.2014.04.010).
Sensitivity analyses were presented in ICER tornado
diagrams. The range for the utility value (0.63–0.85)
for treatment success was taken from a published
study18 that evaluated the cost-effectiveness of sacral
neuromodulation for FI.June 2014A cost-effectiveness acceptability curve was com-
puted to evaluate the relationship between willingness-
to-pay (WTP) thresholds and the likelihood of an
intervention being cost-effective (Figure 3). For this
curve, the sum of the respective probabilities is 1 for
the range of WTP values. The WTP threshold ranges
from 0 to $100,000. The net monetary beneﬁt is
used for the computations. The percentage of
iterations favoring each intervention with respect to
a range of WTP thresholds is presented (see the
Supplemental Table II in the online version at http://
dx.doi.org/10.1016/j.clinthera.2014.04.010).
Budget Impact Analysis
A budget impact analysis (BIA) was performed to
estimate the effect of FI treatment with NASHA/Dx
and SNS on health care plan costs. The noninstitu-
tionalized population of US adults was used as the
base population, with estimates of the prevalence of FI
(ie, 2.7%) derived from published sources.39,40 Effect
estimates were based on a health care plan with
1,000,000 covered lives. NASHA/Dx is a relatively
new intervention; hence, its use is not well known.
The proportion of the population who seek care is
25%, and an estimated 80% of this population will
initially be treated with CT.18 The estimated CT
failure rate was 25%.18 The BIA was performed
using a range of 5% to 25% for the likelihood that895
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Figure 3. Cost-effectiveness Acceptability Curve. NASHA Dx = non–animal stabilized hyaluronic acid and
dextranomer copolymer; SNS = sacral nerve stimulation.
Clinical Therapeuticspatients would choose or be assigned to NASHA/Dx.
The BIA is computed for patients who are good
candidates for both NASHA/Dx and SNS. The net
effect to the health care payer is computed for the
scenario when all patients receive NASHA/Dx, for a
scenario when all patients receive SNS, and for a set of
intermediate scenarios. The BIA was performed using
Microsoft Excel 2010 (Microsoft Corp).
RESULTS
The cost-effectiveness models evaluated 2 end points:
QALYs and IFDs. For the 3-year cost-effectiveness
models (for both outcomes), the costs for CT, NA-
SHA/Dx, and SNS were $9053, $14,968, and
$33,201, respectively (Table III). Total IFDs during
the 3-year periods associated with CT, NASHA/Dx,
and SNS were 128.8, 267.6, and 514.8 days, respec-
tively. The incremental costs per QALY gained were
$37,036 for NASHA/Dx versus CT and $244,509 for
SNS versus NASHA/Dx. The incremental cost per
QALY gained for SNS versus CT was $103,066. The896ICERs per additional IFD gained were $42.60 for
NASHA/Dx versus CT, $73.76 for SNS versus NA-
SHA/Dx, and $62.55 for SNS versus CT.
The cost-effectiveness acceptability curve presents
the likelihood that the interventions are cost-effective
over a range of WTP thresholds (Figure 3,
Supplemental Table II in the online version at
http://dx.doi.org/10.1016/j.clinthera.2014.04.010). For
NASHA/Dx, 59% of simulations would be cost-
effective at a WTP threshold of $50,000 and 63% at
a WTP of $100,000. At a WTP of $40,000 per QALY,
53% of the simulations for NASHA/Dx would be cost-
effective, which is slightly higher when compared with
CT (46%). In comparison, SNS had only a 3%
probability of cost-effectiveness at a WTP of $50,000
and 16% at $100,000.
The BIA was computed for a range of ratios for the
use of NASHA/Dx and SNS. When all of the patients
receive NASHA/Dx, the net annual effect to the health
care payer budget ranged from $571,455 to $2,857,275
(Table IV). When all of the patients receive SNS, theVolume 36 Number 6
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Figure 4. Tornado Diagram (ICER for NASHA/Dx vs CT). NASHA/Dx = non–animal stabilized hyaluronic
acid and dextranomer copolymer; SNS = sacral nerve stimulation; CT = conservative therapy;
ICER = incremental cost-effectiveness ratio; Trt = treatment; Phys = physician; Imp = implantation;
EV = expected value; Stim = stimulation.
M.A. Bernstein et al.net annual effect to the health care payer budget ranged
from $1,959,323 to $9,796,613. Intermediate scena-
rios, where the use of both NASHA/Dx and SNS
range from 25% to 75%, are also presented. Because
the acquisition cost of NASHA/Dx is signiﬁcantly
less than SNS, the scenarios that favor more use of
NASHA/Dx present less net effect to the health care
payer.
Results of the 1-way sensitivity analysis computed
for the NASHA/Dx treatment cost appear in Table V.
The base case cost for the NASHA/Dx treatment was
$4900, and this value ranged from $2940 to $6860.
Under this range of scenarios, the incremental cost per
additional QALY gained for NASHA/Dx versus CT
ranged from $16,986 to $57,086. The incremental
cost per additional QALY gained for SNS versus
NASHA/Dx ranged from $287,458 to $201,560.June 2014Under all scenarios, the incremental cost per QALY
gained for NASHA/Dx was signiﬁcantly less than the
comparable value for SNS.
A 1-way sensitivity analysis was computed for the
decrease in medical management costs for treatment
responders (Table VI). The base case cost for the
percentage of decrease in medical management costs
for treatment responders was 50%; this value ranged
from 0% to 50% in the sensitivity analysis. Under this
range of scenarios, the incremental cost per additional
QALY gained for NASHA/Dx versus CT ranged from
$22,005 to $37,036. The incremental cost per addi-
tional QALY gained for SNS versus NASHA/Dx ranged
from $244,036 to $244,509. Under all scenarios, the
incremental cost per QALY gained for NASHA/Dx was
signiﬁcantly less than the comparable value for
SNS.897
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Clinical TherapeuticsA 1-way sensitivity analysis was computed for the
NASHA/Dx subsequent treatment rate (Table VII).
The base case for the retreatment rate is 63.4%, and
this value ranged from 33% to 82% in the sensitivity
analysis. Under this range of scenarios, the
incremental cost per additional QALY gained for
NASHA/Dx versus CT ranged from $27,175 to
$43,069. The incremental cost per additional QALY
gained for SNS versus NASHA/Dx ranged from
$231,586 to $265,631. Under all scenarios, the
incremental cost per QALY gained for NASHA/Dx
was signiﬁcantly less than the comparable value
for SNS.
The tornado diagrams for the ICERs indicate the
variables that have the most effect on the incremental
costs per QALYs gained (Figures 4–6). In all cases, the
variable that is most able to inﬂuence the ICERs is the
utility value for treatment success. For the ICER for898NASHA/Dx versus CT, the next 2 most inﬂuential
variables are the cost for the NASHA/Dx treatment
and the utility value for nonresponders (ie, treat-
ment failure). The expected value for the ICER in
this sensitivity analysis ranges from approximately
$10,000 to $100,000 per incremental QALY gained
(Figure 4). For the ICER for SNS versus NASHA/Dx,
the next 2 most inﬂuential variables were the success
rate for the SNS implantation procedure and the
NASHA/Dx success rate. The expected value for
the ICER in this sensitivity analysis ranges from
approximately $150,000 to $600,000 per incre-
mental QALY gained (Figure 5). For the ICER for
SNS versus NASHA/Dx, the next 2 most inﬂuential
variables were the utility value for nonresponders (ie
treatment failure) and the SNS permanent
implantation cost. The expected value for the ICER
in this sensitivity analysis ranged from approximatelyVolume 36 Number 6
Utility (Success) (0.63 to 0.85)
Utility (Failure) (0.5 to 0.6)
SNS Imp Cost (17788.0 to
26682.0) 
SNS Imp Success Rate (0.7438 to
0.8882)
SNS Stim Success Rate (0.8278
to 0.9722)
SNS Stim Cost (5433.0 to 8150.0)
Cons Trt Cost (2067.0 to 3101.0)
Biofeedback Success (0.1 to 0.5)
Biofeedback Cost Month (212.36
to 318.55)
NASHA/Dx Success Rate
(0.5471 to 0.6515)  
NASHA/Dx Retreat Rate (0.33 to
0.82)
NASHA/Dx Phys Cost (224.82
to 337.23)
NASHA/Dx Cost (2940.0 to
6860.0
Cons Trt Success Rate (0.2547
to 0.3653)
EV: 103,066.44816
60,000 80,000 100,000 120,000 140,000 160,000 180,000 200,000 220,000 240,000 260,000
Figure 6. Tornado Diagram (ICER for SNS vs CT). NASHA/Dx = non–animal stabilized hyaluronic acid and
dextranomer copolymer; SNS = sacral nerve stimulation; CT = conservative therapy; ICER =
incremental cost-effectiveness ratio; Trt = treatment; Phys = physician; Imp = implantation; EV =
expected value; Stim = stimulation.
M.A. Bernstein et al.$60,000 to $260,000 per incremental QALY gained
(Figure 6).
DISCUSSION
Fecal incontinence imposes a substantial health and
economic burden on the US population; the estimates
of the prevalence of this condition in some form have
been as high as 24% in the general population but
generally range from 2% to 8%.39–42 For physicians
and patients, there will undoubtedly be a variety of
factors that affect decisions related to treatment options
when CT has been proven unsatisfactory. From the
patient’s point of view, the less invasive nature of theJune 2014NASHA/Dx injectable and the favorable adverse event
proﬁle may make it an attractive intermediate option
between CT and surgical options (eg, anal sphincter-
oplasty and sacral nerve stimulation).
From the payers’ point of view, FI exerts a substantial
economic effect on the health care system. The costs
associated with CT for FI (eg, dietary changes and
biofeedback) are relatively low when compared with the
costs associated with the treatment options when CT is
not sufﬁciently effective. In the United States, the currently
available treatment options after CT failure are NASHA/
Dx, SNS, and anal sphincteroplasty. Although the costs
associated with NASHA/Dx are not insigniﬁcant, they are899
Table III. Results of the cost-effectiveness base case analysis.*
Group and Outcome
Expected
Cost, $
Incremental
Cost, $ Effectiveness†
Incremental
Effectiveness
ICER‡ (ΔCost/
ΔEffect)
Conservative therapy
Utility 9053 1.769
IFD 9053 128.78
NASHA/Dx§
Utility 14,968 5915 1.929 0.160 37,036
IFD 14,968 5915 267.61 138.83 42.60
Sacral nerve stimulation
Utility 33,201 18,233 2.004 0.075 244,509
IFD 33,201 18,233 514.81 247.20 73.76
Sacral nerve stimulation
baseline║
Utility 33,201 24,148 2.004 0.235 103,066
IFD 33,201 24,148 514.81 386.03 62.55
ICER ¼ incremental cost-effectiveness ratio; IFD ¼ incontinence-free day; NASHA/Dx ¼ non–animal stabilized hyaluronic
acid and dextranomer copolymer.
*All costs are in 2013 US dollars
†Effectiveness is measured in quality-adjusted life-years for the utility model and IFDs for the IFD model.
‡The ICER effect is measured in quality-adjusted life years for the utility model and IFDs for the IFD model.
§Base case has a 63.4% subsequent treatment rate for NASHA/Dx.
║The ICER is computed based on common baseline (ie, conservative therapy).
Clinical Therapeuticsmuch less than for surgical treatment. When compared
with SNS, the acquisition cost for the ﬁrst treatment of
NASHA/Dx represents only 18% of the cost for full SNS
implantation. If subsequent treatment for all patients isTable IV. Budget impact analysis (per 1 million covered
Proportion
Given
NASHA/
Dx, %
No.
Treated
NASHA/Dx
Cost, $
SNS
Cost, $
Effect for
100%
NASHA/
Dx, $
Eff
N
5 68 8466 29,027 571,455
10 135 8466 29,027 1,142,910 1
15 203 8466 29,027 1,714,365 2
20 270 8466 29,027 2,285,820 3
25 338 8466 29,027 2,857,275 4
NASHA/Dx ¼ non–animal stabilized hyaluronic acid and dextra
900assumed, the costs for NASHA/Dx still only represent
approximately 36% of the SNS cost.
Considering the high prevalence and economic
burden, as well as the associated negative effect onlives annually)
ect for 75%
ASHA/Dx
and 25%
SNS, $
Effect for 50%
NASHA/Dx
and 50%
SNS, $
Effect for 25%
NASHA/Dx
and 75%
SNS, $
Effect for
100% SNS,
$
918,422 1,265,389 1,612,356 1,959,323
,836,844 2,530,778 3,224,711 3,918,645
,755,266 3,796,166 4,837,067 5,877,968
,673,688 5,061,555 6,449,423 7,837,290
,592,109 6,326,944 8,061,778 9,796,613
nomer copolymer; SNS ¼ sacral nerve stimulation.
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Table V. One-way sensitivity analysis for NASHA/Dx cost input.
NASHA/Dx
Treatment Cost, $
CT Arm
Cost, $
NASHA/Dx Arm
Cost, $
SNS Arm
Cost, $
ICER (NASHA/Dx
vs CT), $
ICER (SNS vs
NASHA/Dx), $
2940 $9053 11,766 33,201 16,986 287,458
3920 $9053 13,367 33,201 27,011 265,984
4900 $9053 14,968 33,201 37,036 244,509
5880 $9053 16,570 33,201 47,061 223,035
6860 $9053 18,171 33,201 57,806 201,560
CT ¼ conservative therapy; ICER ¼ incremental cost-effectiveness ratio; NASHA/Dx ¼ non–animal stabilized hyaluronic acid
and dextranomer copolymer; SNS ¼ sacral nerve stimulation.
M.A. Bernstein et al.quality of life, appropriate intervention for manage-
ment of FI is important. NASHA/Dx and SNS are
relatively new interventions in the United States,
and both have produced signiﬁcant clinical
beneﬁts.4,9–13,15,26–30,43,45 NASHA/Dx has some sig-
niﬁcant advantages, such as being less invasive and
less costly, when compared with SNS. NASHA/Dx
also has a good safety proﬁle. One option for
physicians and patients to consider would be to use
NASHA/Dx before surgical options; if this procedure
does not yield adequate results, then surgery would
remain as a possible next step.
Our results are similar to those from other analy-
ses, especially the studies from France22 and the
United Kingdom,19 in that patients experienced
improvements in FI episodes and quality of life but
at an increased cost. However, the ICERs appear to beTable VI. One-way sensitivity analysis for medical mana
Medical Management
Decrease, %
CT Arm
Cost, $
NASHA/Dx
Arm Cost, $
0 9053 12,568
10 9053 13,048
20 9053 13,528
30 9053 14,008
40 9053 14,488
50 9053 14,968
CT ¼ conservative therapy; ICER ¼ incremental cost-effectivenes
and dextranomer copolymer; SNS ¼ sacral nerve stimulation.
June 2014fairly reasonable, making NASHA/Dx a cost-effective
choice. According to Laupacis et al,44 this analysis
provides “moderate evidence for adoption and
appropriate utilization” of this new technology.
They also indicated that its cost-effectiveness would
be comparable to that of hospital hemodialysis com-
pared with ambulatory peritoneal dialysis. In contrast,
SNS had only a 3% probability of cost-effectiveness at
a WTP of $50,000 and 16% at $100,000.
The BIA presents the additional costs to the health
care system for patients who are good candidates for
both NASHA/Dx and SNS. The BIA models the input
variables over relatively wide ranges because the real-
world use of NASHA/Dx is not yet well understood.
Initially, NASHA/Dx accrues additional costs for the
health care system; however, this intervention may be
able to provide satisfactory results for at least 50% ofgement cost decrease (for treatment responders).
SNS Arm
Cost, $
ICER (NASHA/Dx
vs CT), $
ICER (SNS vs
NASHA/Dx), $
30,765 22,005 244,036
31,252 25,012 244,130
31,740 28,018 244,225
32,227 31,024 244,320
32,714 34,030 244,414
33,201 37,036 244,509
s ratio; NASHA/Dx ¼ non–animal stabilized hyaluronic acid
901
Table VII. One-way sensitivity analysis for NASHA/Dx subsequent treatment rate.
Medical Management
Decrease, %
CT Arm
Cost, $
NASHA/Dx Arm
Cost, $
SNS Arm
Cost, $
ICER (NASHA/Dx
vs CT), $
ICER (SNS vs
NASHA/Dx), $
33.0 9053 13,393 33,201 27,175 265,631
42.8 9053 13,901 33,201 30,354 258,822
52.6 9053 14,409 33,201 33,533 252,013
62.4 9053 14,917 33,201 36,711 245,204
72.2 9053 15,424 33,201 39,890 238,395
82.0 9053 15,932 33,201 43,069 231,586
CT ¼ conservative therapy; ICER ¼ incremental cost-effectiveness ratio; NASHA/Dx ¼ non–animal stabilized hyaluronic acid
and dextranomer copolymer; SNS ¼ sacral nerve stimulation.
Clinical Therapeuticspatients in whom conservative medical management
fails. NASHA/Dx may provide an opportunity for the
health care payer to positively affect the health status
of their patients and also potentially lessen net
expenditures. Because some patients may be unwilling
to undergo the risks associated with surgical treat-
ment, this technology may represent an opportunity
for health beneﬁts for these patients.
Sensitivity analyses indicate that the cost-effectiveness
results (for the incremental costs per QALY gained) are
robust with respect to moderate deviations in input
values that underlie the value of the NASHA/Dx to the
health care payer. The ICERs for NASHA/Dx, for the
range of sensitivity analyses investigated, all fall within
the range acceptable for the adoption of a new technol-
ogy. The favorable cost-effectiveness of NASHA/Dx for
both outcomes reﬂects the increased beneﬁts to the
patient, which can be acquired for a lower cost. Some
patients may not be able to achieve adequate outcomes
using NASHA/Dx; consequently, they may elect to
proceed to surgical options, such as SNS.
Because both of these technologies have been ap-
proved by the FDA as recently as 2011, the avail-
ability of long-term data is limited. What currently
exist are largely follow-up data from the clinical trials.
This analysis used results from clinical trials, which
may limit the generalizability to real-world practice.
For NASHA/Dx, the length of follow-up available in
the literature was limited to 3 years, hence the period
for this model. For SNS, most of the data available
from the literature is r3 years. However, a few
studies have reported data that report the efﬁcacy
during at least 5 years.17,43 The efﬁcacy estimates for902these studies range from 74% to 89%. An additional
study45 reported the efﬁcacy of SNS treatments for FI
for a median follow-up duration of 114 months; in
this study 48% of the patients maintained full con-
tinence. These studies represent some evidence of the
durability of effect for SNS treatments. The durability
of effect for NASHA/Dx treatments needs to be
evaluated in future research.
One consideration that may be important is the need
for battery replacement for the SNS procedure, which
typically occurs 3 to 5 years after the procedure and
adds to the overall costs and any potential complica-
tions associated with replacement. Although this exam-
ple is stated for SNS, there may also be important long-
term considerations related to NASHA/Dx that have
not been included in this analysis. Only 2 of the
referenced studies included a control group; therefore,
the efﬁcacy estimates for NASHA/Dx and SNS have
been estimated directly from the literature and have not
been standardized through a common comparator.
Another limitation lies in the limited number of
clinical outcomes that are incorporated into this
economic analysis. This analysis is built on the
Responder50 end point and the number of IFDs. These
end points likely capture a large portion of the
improvement in FI; however, there are other end
points that complement the understanding provided
by these outcomes. For instance, the disease-speciﬁc
quality-of-life instruments, including the Fecal Incon-
tinence Quality of Life Scale, are sensitive to improve-
ments in FI patients’ quality of life; however, methods
for quantifying this improvement within the context
of an economic analysis have not yet been established.Volume 36 Number 6
M.A. Bernstein et al.CONCLUSION
NASHA/Dx and SNS have both produced signiﬁcant
improvements in FI symptoms for affected patients.
NASHA/Dx represents a more efﬁcient use of resour-
ces for the treatment of FI when compared with SNS.
The present analysis provides the patient, physician,
and payer with a potential pathway for the manage-
ment of FI for patients whose conditions are not well
controlled with CT. When considering the 2 options
when CT fails, NASHA/Dx should be considered as
the ﬁrst option because it provides a less invasive and
lower cost intervention, which also has the beneﬁt of
reducing by 450% the population who may proceed
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Supplemental Survey 1. Physician Practice Pattern (for Fecal Incontinence) Survey.
1. How many fecal incontinence (FI) patients would you see per month in your practice?
i. Less than 5 □
ii. Between 5 and 10 □
iii. Between 10 and 15 □
iv. Between 15 and 25 □
v. More than 25 □
2. For your practice, what percentage of FI patients who are female? _ __ __ _%
3. Do you use any of the following instruments to assess the severity of FI in normal clinical practice?
Please circle any of the following which apply:
i. Do not use any instrument
ii. Fecal Incontinence Quality of Life Scale
iii. Cleveland Clinic Florida/Wexner Incontinence Score
iv. Other _ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ _
4. What is your ﬁrst-line therapy for the management of minor fecal incontinence?
Please circle any of the following which apply:
i. Dietary Changes (ie, Supplementary Fibers)
ii. Antidiarrheal Medications
iii. Biofeedback Training
iv. Other (please indicate) _ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ _
5. Which of the following do you use in the evaluation of fecal incontinence patients?
Please circle any of the following which apply:
i. Anoscopy/Proctoscopy/Sigmoidoscopy
ii. Anorectal Manometry
iii. Anal Endosonography
iv. Defecography
v. Pudendal Nerve Terminal Motor Latency
vi. Other (please indicate) _ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ _
6. If ﬁrst-line therapy for minor FI is not successful, please indicate your treatment preference.Please rank from
1-5 with 1 being the most often recommended:
i. Injectable Bulking Agent _ __ __ __ __ _
ii. Sacral Nerve Stimulation (SNS) _ __ __ __ __ _
iii. Sphincteroplasty _ __ __ __ __ _
iv. Radiofrequency treatment of the anal canal _ __ __ __ __ _
v. Other _ __ __ __ __ _ If “Other” please indicate: _ __ __ __ __ __ __ __ __ __ __ __ __ __ _
7. If you were to use injectable bulking agents over SNS, please indicate why (check all that apply):
i. Better outcome □
ii. Low risk of complication □
iii. Patient preference □
iv. Good reimbursement □
v. Better experience with injectable bulking agents □
vi. Durability for response □
vii. Other □
(continued)
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Supplemental Survey 1. (continued).
If “Other” please explain: _ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __
__ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ _
8.
If you were to use SNS over injectable bulking agents, please indicate why (check all that apply):
i. Better outcome □
ii. Low risk of complication □
iii. Patient preference □
iv. Good reimbursement □
v. Better experience with SNS □
vi. Durability for response □
vii. Other □
If “Other” please explain: _ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __
__ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __
__ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __
9. If you have used injectable bulking agents for the treatment of FI and treatment was not successful; what is
your next treatment option? Please explain. _ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __
__ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __
__ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __
__ __ __ __ __ __ __ __ __ __ __ __ __ __ __
10. How does the condition of the anal sphincter (ie, intact or structurally deﬁcient) affect the treatment
algorithm for the FI patient? Please explain._ __ __ __ __ __
M.A. Bernstein et al.
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Supplemental Table I. Distributions for probabilistic sensitivity analysis.*
Distribution Distribution Type Parameter 1† Parameter 2‡
Utility (success) β 14.2376 5.0024
Utility (failure) β 13.6125 11.1375
Conservative treatment success β 21.6831 48.2625
Biofeedback treatment success β 3.2000 12.8000
NASHA/Dx treatment success β 52.8175 35.3101
SNS stimulation treatment success β 15.5386 1.7265
SNS implantation treatment success β 23.5030 5.2997
No FI symptoms (conditional on no FI symptoms) β 18.0500 0.9500
No FI symptoms (conditional on FI Symptoms
without TRT)§
β 1.9125 10.8375
Conservative treatment cost LogNormal 7.7517 0.4590
Biofeedback treatment cost (month) LogNormal 5.4761 0.4591
NASHA/Dx treatment cost LogNormal 8.3916 0.4590
NASHA/Dx physician cost LogNormal 5.5331 0.4590
SNS stimulation cost LogNormal 8.7182 0.4590
SNS implantation cost LogNormal 9.9581 0.3203
FI ¼ fecal incontinence; NASHA/Dx ¼ non–animal stabilized hyaluronic acid and dextranomer copolymer; SNS ¼ sacral
nerve stimulation; TRT ¼ treatment.
*Monte-Carlo simulation with 10,000 iterations.
†For LogNormal distributions, parameter 1 is μ; for β distributions, parameter 1 is α.
‡For LogNormal distributions, parameter 2 is s; for β distributions, parameter 2 is β.
§The Prob(FI symptoms | FI Symptoms without treatment) ¼ 1 – Prob(No FI Symptoms | FI Symptoms without TRT) ¼ 0.85.
Clinical TherapeuticsSupplemental Table II. Strategy selection by WTP thresholds.*
WTP Threshold,
US$
Iterations Favoring
SNS, %
Iterations Favoring
NASHA/Dx, %
Iterations Favoring
CT, %
0 0.0 2.7 97.3
25,000 0.3 37.0 62.7
40,000 1.6 52.8 45.6
50,000 3.3 58.9 37.8
75,000 9.1 64.2 26.7
100,000 16.1 62.6 21.3
WTP ¼ willingness to pay.
*Probabilistic sensitivity analysis results used for this analysis and for the cost-effectiveness acceptability curve (Figure 3,
Figure 2).
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